Immunotherapy of melanoma

European Journal of Cancer, Supplement

Volumn 11, Issue 2, 2013, Pages 97-105

  Haanen, John B A G ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DABRAFENIB; DACARBAZINE; FLUDARABINE; GLYCOPROTEIN GP 100; HLA A ANTIGEN; INFLIXIMAB; INTERLEUKIN 15; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 7; IPILIMUMAB; NIVOLUMAB; PROGRAMMED DEATH 1 LIGAND 1; PROTEIN TYROSINE PHOSPHATASE SHP 2; TICILIMUMAB; TRAMETINIB; VEMURAFENIB;

ADAPTIVE IMMUNITY; ANEMIA; ANTIGEN BINDING; ANTIGEN PRESENTING CELL; ASEPTIC MENINGITIS; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CANCER REGRESSION; CANCER SURVIVAL; CELL INFILTRATION; CELL THERAPY; CHILL; COLITIS; CONFERENCE PAPER; CORTICOSTEROID THERAPY; CUTANEOUS MELANOMA; DERMATITIS; DIARRHEA; DNA MODIFICATION; DRESS SYNDROME; DRUG MEGADOSE; EOSINOPHILIA; FATIGUE; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; GASTRITIS; GENE EXPRESSION; HEART MUSCLE FIBROSIS; HEMATOPOIETIC STEM CELL; HEPATITIS; HUMAN; HYPOPHYSITIS; HYPOTENSION; INTENSIVE CARE UNIT; INTESTINE PERFORATION; KIDNEY CARCINOMA; KIDNEY METASTASIS; LEUKOPENIA; LUNG ALVEOLITIS; LUNG NON SMALL CELL CANCER; LYMPHOCYTE COUNT; LYMPHOCYTOPENIA; MAXIMUM TOLERATED DOSE; MELANOMA; METASTASIS; METASTATIC MELANOMA; MUSCULOSKELETAL DISEASE; NAUSEA; NEPHRITIS; NONHUMAN; OVERALL SURVIVAL; PANCREATITIS; PRIMARY TUMOR; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REGULATORY T LYMPHOCYTE; RETROVIRUS INFECTION; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR ASSOCIATED LEUKOCYTE; WEIGHT GAIN; WHOLE BODY RADIATION;

EID: 84884971761     PISSN: 13596349     EISSN: 18781217     Source Type: Journal    
DOI: 10.1016/j.ejcsup.2013.07.013     Document Type: Conference Paper

References (75)

1. Bennett W.H. Lancet 1899, 1:3.
2. Jakob J.A., Bassett R.L., Ng C.S., et al. NRAS mutation status is an independent prognostic factor in metastatic melanoma. Cancer 2012, 118(16):4014-4023.
3. Kalialis L.V., Drzewiecki K.T., Klyver H. Spontaneous regression of metastases from melanoma: review of the literature. Melanoma Res 2009, 19(5):275-282.
4. Oble D.A., Loewe R., Yu P., et al. Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human melanoma. Cancer Immun 2009, 9:3.
5. Clemente C.G., Mihm M.C., Bufalino R., et al. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer 1996, 77(7):1303-1310.
6. Erdag G., Schaefer J.T., Smolkin M.E., et al. Immunotype and immunohistologic characteristics of tumor-infiltrating immune cells are associated with clinical outcome in metastatic melanoma. Cancer Res 2012, 72(5):1070-1080.
7. Bakker A.B., Schreurs M.W., de Boer A.J., et al. Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes. J Exp Med 1994, 179(3):1005-1009.
8. Brichard V., Van Pel A., Wolfel T., et al. The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med 1993, 178(2):489-495.
9. Castelli C., Storkus W.J., Maeurer M.J., et al. Mass spectrometric identification of a naturally processed melanoma peptide recognized by CD8+ cytotoxic T lymphocytes. J Exp Med 1995, 181(1):363-368.
10. Gaugler B., Van den Eynde B., van der Bruggen P., et al. Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. J Exp Med 1994, 179(3):921-930.
11. Huang L.Q., Brasseur F., Serrano A., et al. Cytolytic T lymphocytes recognize an antigen encoded by MAGE-A10 on a human melanoma. J Immunol 1999, 162(11):6849-6854.
12. Jager E., Chen Y.T., Drijfhout J.W., et al. Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. J Exp Med 1998, 187(2):265-270.
13. Kawakami Y., Eliyahu S., Delgado C.H., et al. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc Natl Acad Sci U S A 1994, 91(9):3515-3519.
14. Kvistborg P., Shu C.J., Heemskerk B., et al. TIL therapy broadens the tumor-reactive CD8(+) T cell compartment in melanoma patients. Oncoimmunology 2012, 1(4):409-418.
15. Romero P., Gervois N., Schneider J., et al. Cytolytic T lymphocyte recognition of the immunodominant HLA-A*0201-restricted Melan-A/MART-1 antigenic peptide in melanoma. J Immunol 1997, 159(5):2366-2374.
16. Traversari C., van der Bruggen P., Luescher I.F., et al. A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E. J Exp Med 1992, 176(5):1453-1457.
17. Hodis E., Watson I.R., Kryukov G.V., et al. A landscape of driver mutations in melanoma. Cell 2012, 150(2):251-263.
18. Krauthammer M., Kong Y., Ha B.H., et al. Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma. Nat Genet 2012, 44(9):1006-1014.
19. Rosenberg S.A., Yang J.C., White D.E., et al. Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response. Ann Surg 1998, 228(3):307-319.
20. Kammula U.S., White D.E., Rosenberg S.A. Trends in the safety of high dose bolus interleukin-2 administration in patients with metastatic cancer. Cancer 1998, 83(4):797-805.
21. Atkins M.B., Lotze M.T., Dutcher J.P., et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 1999, 17(7):2105-2116.
22. Morgan D.A., Ruscetti F.W., Gallo R. Selective in vitro growth of T lymphocytes from normal human bone marrows. Science 1976, 193(4257):1007-1008.
23. Joseph R.W., Sullivan R.J., Harrell R., et al. Correlation of NRAS mutations with clinical response to high-dose IL-2 in patients with advanced melanoma. J Immunother 2012, 35(1):66-72.
24. Weiss G.R., Grosh W.W., Chianese-Bullock K.A., et al. Molecular insights on the peripheral and intratumoral effects of systemic high-dose rIL-2 (aldesleukin) administration for the treatment of metastatic melanoma. Clin Cancer Res 2011, 17(23):7440-7450.
25. Lee D.S., White D.E., Hurst R., et al. Patterns of relapse and response to retreatment in patients with metastatic melanoma or renal cell carcinoma who responded to interleukin-2-based immunotherapy. Cancer J Sci Am 1998, 4(2):86-93.
26. Rosenberg S.A., Lotze M.T., Yang J.C., et al. Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg 1989, 210(4):474-484. [discussion 484-5].
27. Schwartzentruber D.J., Lawson D.H., Richards J.M., et al. Gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med 2011, 364(22):2119-2127.
28. Seung S.K., Curti B.D., Crittenden M., et al. Phase 1 study of stereotactic body radiotherapy and interleukin-2 - tumor and immunological responses. Sci Transl Med 2012, 4(137):137ra74.
29. Maker A.V., Phan G.Q., Attia P., et al. Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study. Ann Surg Oncol 2005, 12(12):1005-1016.
30. Dudley M.E., Wunderlich J.R., Robbins P.F., et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002, 298(5594):850-854.
31. Brunet J.F., Denizot F., Luciani M.F., et al. A new member of the immunoglobulin superfamily - CTLA-4. Nature 1987, 328(6127):267-270.
32. Pentcheva-Hoang T., Egen J.G., Wojnoonski K., et al. B7-1 and B7-2 selectively recruit CTLA-4 and CD28 to the immunological synapse. Immunity 2004, 21(3):401-413.
33. Peggs K.S., Quezada S.A., Allison J.P. Cell intrinsic mechanisms of T-cell inhibition and application to cancer therapy. Immunol Rev 2008, 224:141-165.
34. Waterhouse P., Penninger J.M., Timms E., et al. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science 1995, 270(5238):985-988.
35. Grosso J.F., Jure-Kunkel M.N. CTLA-4 blockade in tumor models: an overview of preclinical and translational research. Cancer Immun 2013, 13:5.
36. van Elsas A., Hurwitz A.A., Allison J.P. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J Exp Med 1999, 190(3):355-366.
37. Pardoll D.M. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012, 12(4):252-264.
38. Phan G.Q., Yang J.C., Sherry R.M., et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A 2003, 100(14):8372-8377.
39. Ribas A., Camacho L.H., Lopez-Berestein G., et al. Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206. J Clin Oncol 2005, 23(35):8968-8977.
40. Weber J., Thompson J.A., Hamid O., et al. A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin Cancer Res 2009, 15(17):5591-5598.
41. Hodi F.S., O'Day S.J., McDermott D.F., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010, 363(8):711-723.
42. Robert C., Thomas L., Bondarenko I., et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011, 364(26):2517-2526.
43. Ribas A., Chesney J.A., Gordon M.S., et al. Safety profile and pharmacokinetic analyses of the anti-CTLA4 antibody tremelimumab administered as a one hour infusion. J Transl Med 2012, 10:236.
44. Ribas A., Kefford R., Marshall M.A., et al. Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol 2013, 31(5):616-622.
45. Voskens C.J., Goldinger S.M., Loquai C., et al. The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network. PLoS One 2013, 8(1):e53745.
46. Wilgenhof S., Neyns B. Anti-CTLA-4 antibody-induced Guillain-Barre syndrome in a melanoma patient. Ann Oncol 2011, 22(4):991-993.
47. Vogel W.V., Guislain A., Kvistborg P., et al. Ipilimumab-induced sarcoidosis in a patient with metastatic melanoma undergoing complete remission. J Clin Oncol 2012, 30(2):e7-e10.
48. Callahan M.K., Wolchok J.D., Allison J.P. Anti-CTLA-4 antibody therapy: immune monitoring during clinical development of a novel immunotherapy. Semin Oncol 2010, 37(5):473-484.
49. Delyon J., Mateus C., Lefeuvre D., et al. Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival. Ann Oncol 2013, 24:1697-1703.
50. Nishimura H., Honjo T. PD-1: an inhibitory immunoreceptor involved in peripheral tolerance. Trends Immunol 2001, 22(5):265-268.
51. Chemnitz J.M., Parry R.V., Nichols K.E., et al. SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation. J Immunol 2004, 173(2):945-954.
52. Latchman Y., Wood C.R., Chernova T., et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol 2001, 2(3):261-268.
53. Blank C., Gajewski T.F., Mackensen A. Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy. Cancer Immunol Immunother 2005, 54(4):307-314.
54. Dong H., Strome S.E., Salomao D.R., et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 2002, 8(8):793-800.
55. Taube J.M., Anders R.A., Young G.D., et al. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med 2012, 4(127):127ra37.
56. Brahmer J.R., Drake C.G., Wollner I., et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 2010, 28(19):3167-3175.
57. Topalian S.L., Hodi F.S., Brahmer J.R., et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012, 366(26):2443-2454.
58. Brahmer J.R., Tykodi S.S., Chow L.Q., et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012, 366(26):2455-2465.
59. Rosenberg S.A., Lotze M.T., Yang J.C., et al. Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. J Natl Cancer Inst 1993, 85(8):622-632.
60. Dudley M.E., Wunderlich J.R., Yang J.C., et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 2005, 23(10):2346-2357.
61. Gattinoni L., Finkelstein S.E., Klebanoff C.A., et al. Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. J Exp Med 2005, 202(7):907-912.
62. Dudley M.E., Yang J.C., Sherry R., et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol 2008, 26(32):5233-5239.
63. Dudley M.E., Gross C.A., Langhan M.M., et al. CD8+ enriched "young" tumor infiltrating lymphocytes can mediate regression of metastatic melanoma. Clin Cancer Res 2010, 16(24):6122-6131.
64. Besser M.J., Shapira-Frommer R., Treves A.J., et al. Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients. Clin Cancer Res 2010, 16(9):2646-2655.
65. Joseph R.W., Peddareddigari V.R., Liu P., et al. Impact of clinical and pathologic features on tumor-infiltrating lymphocyte expansion from surgically excised melanoma metastases for adoptive T-cell therapy. Clin Cancer Res 2011, 17(14):4882-4891.
66. Pilon-Thomas S., Kuhn L., Ellwanger S., et al. Efficacy of adoptive cell transfer of tumor-infiltrating lymphocytes after lymphopenia induction for metastatic melanoma. J Immunother 2012, 35(8):615-620.
67. Schumacher T.N. T-cell-receptor gene therapy. Nat Rev Immunol 2002, 2(7):512-519.
68. Gross G., Waks T., Eshhar Z. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc Natl Acad Sci U S A 1989, 86(24):10024-10028.
69. Brentjens R.J., Riviere I., Park J.H., et al. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood 2011, 118(18):4817-4828.
70. Grupp S.A., Kalos M., Barrett D., et al. Chimeric antigen receptor-modified t cells for acute lymphoid leukemia. N Engl J Med 2013.
71. Porter D.L., Levine B.L., Kalos M., et al. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 2011, 365(8):725-733.
72. Johnson L.A., Morgan R.A., Dudley M.E., et al. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 2009, 114(3):535-546.
73. Morgan R.A., Chinnasamy N., Abate-Daga D., et al. Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J Immunother 2013, 36(2):133-151.
74. Morgan R.A., Dudley M.E., Wunderlich J.R., et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 2006, 314(5796):126-129.
75. Robbins P.F., Morgan R.A., Feldman S.A., et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol 2011, 29(7):917-924.